A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton#s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma